Target intelligence / Profile preview

Epstein-Barr virus nuclear antigen (EBNA (for the family); for individual proteins, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP[3][5][6][4])

Target: EBNA (for the family); for individual proteins, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP[3][5][6][4]
Molecular classification: DNA-binding protein (EBNA1)[1][3][7], Transcription factor (EBNA2, EBNA3A, EBNA3B, EBNA3C)[5][6], Chromosome tethering protein (EBNA1)[4][7], Coactivator (EBNA-LP)[6]

Overview

The Epstein-Barr nuclear antigen family encompasses several proteins encoded by the EBV genome that regulate key aspects of viral latency, replication, and cell transformation. EBNA1 is critical for viral episome maintenance during latency, binding specific sequences at the origin of plasmid replication (oriP) and tethering EBV DNA to host chromosomes[1][2][3][7][4]. EBNA2 activates transcription of both viral and cellular genes, mimicking Notch signaling pathways and collaborating with EBNA-LP[6]. The EBNA3 proteins (EBNA3A, EBNA3B, EBNA3C) act as transcriptional regulators, interact with cellular proteins, and are essential for B-cell transformation and lymphomagenesis[5]. EBNA-LP enhances the transcriptional activity of EBNA2, influencing cell immortalization[6]. Collectively, the EBNA family orchestrates viral persistence, immune evasion, and oncogenic potential, making them important targets for research into EBV-related diseases and therapies[3][4][5][6][7].

Other names: EBNA familyEBNAsEpstein-Barr virus nuclear antigens

Mechanism of action

Potential mechanism: Small molecules or RNAi designed to disrupt DNA binding or protein-protein interactions, inhibit EBNA-mediated episome maintenance or transcriptional activity[4]

Biological functions

DNA replication and episome maintenance (EBNA1)[1][2][3][7]Transcriptional regulation (EBNA2, EBNA3 proteins, EBNA-LP)[5][6][3]Cell immortalization and proliferation (EBNA2, EBNA3A, EBNA3C)[5][6]Immune evasion (EBNA1 via glycine–alanine repeats)[3]

Disease associations

Cancer (EBNA1 is found in all EBV-associated malignancies; EBNA2/EBNA3 linked to lymphoma and cell transformation)[3][5]Infection (core in EBV latent and lytic infection)[3][5][4]

Safety considerations

Targeting EBNAs poses challenges due to high sequence similarity with host proteins, risk of off-target effects, and potential for disrupting host cell processes critical for EBV latency[4]

Interacting drugs

No approved drugs directly target EBNAs in clinical practice; EBNA1 is considered a primary target for future antiviral development[4]

Biomarkers

EBNA1 expression is a biomarker for EBV infection and EBV-related malignancies[3][4]

Beyond the preview

Go deeper on Epstein-Barr virus nuclear antigen (EBNA (for the family); for individual proteins, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP[3][5][6][4]).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus nuclear antigen (EBNA (for the family); for individual proteins, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP[3][5][6][4]).

Explore the full profile